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Abstract
Background: Hyperthyroidism is associated with anxiety symptoms.
Objectives: The aim of this study was to compare the clinical characteristics of patients with anxiety due to hyperthyroidism with
patients with generalized anxiety disorder (GAD).
Materials andMethods: This study was carried out in Abolfazl psychiatry clinic affiliated to Bushehr University of Medical Sciences
from September 2012 to September 2013. Anxiety severity and characteristics of thirty-two patients with GAD was compared to 34 pa-
tients with anxiety due to hyperthyroidism. Hamilton anxiety rating scale (HAM-A) was used to evaluate the overall anxiety severity
and anxiety symptom profile of the two groups.
Results: There was no significant difference regarding overall anxiety severity between the two groups (P = 0.65). Autonomic symp-
toms were more sever in hyperthyroid patients (P = 0.003) whereas anxious mood and fears were more prominent in patients with
GAD (P = 0.001 and P = 0.045, respectively).
Conclusions: This study demonstrated that patients with GAD reported more psychology symptoms of anxiety whereas physical
symptoms of anxiety were more prominent in hyperthyroid patients. Our findings may help differentiate these two disorders in the
clinic, based on the symptom profile. However, it is important to note that this study is preliminary, and larger studies are needed
to confirm the results.
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1. Background
Generalized anxiety disorder (GAD) is a common psy-
chiatric disorder with a one-year prevalence rate of 1.2% to
1.9% and lifetime prevalence rate of 4.3% to 5.9% (1). It con-
sists of both psychology and physical symptoms. Excessive
worry, muscle tension, headache, restlessness, nausea, ex-
cessive sweating and change in bowel pattern are some of
the presentations of this disorder (2).
Thyroid hormones play an important role in the matu-
ration and proper function of the central nervous system
(3). Hyperthyroidism is associated with both physical and
psychological symptoms. The somatic symptoms include
weight loss, tachycardia, excessive sweating, increased ap-
petite, tremor and changes in bowel patterns (4). Two third
of patients with thyroid disease have been reported to have
psychological symptoms (5, 6). Hyperthyroidism has been
associated with anxiety, depression, irritability, insomnia
and low concentration in several studies (7, 8). The psychi-
atry symptoms of hyperthyroidism have been reported to
be similar to generalized anxiety disorder (9).
As GAD and hyperthyroidism have similar symptoms,
differentiating GAD from hyperthyroidism is a challenge
in clinical settings. In this study, the anxiety symptoms of
GAD were compared with anxiety symptoms induced by
hyperthyroidism. Our aim was to study weather these two
disorders can be differentiated by specific anxiety symp-
toms.
2. Materials andMethods
This study was carried out in Abolfazl psychiatry clinic
affiliated to Bushehr University of Medical Sciences from
September 2012 to September 2013. Overall, 32 patients
with generalized anxiety disorder (GAD), according to Di-
agnostic and statistical manual of mental disorders, fourth
edition (DSM-IV) criteria and 34 patients with hyperthy-
roidism and anxiety complaints, according to lab data and
clinical interview, were enrolled.
The patients with GAD were diagnosed according to
DSM-IV criteria using a structured clinical interview for
DSM-IV, clinical version (SCID-I) (10). The interview was
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done by a board certified psychiatrist. Thyroid functioning
tests were in the normal range in this group. Exclusion cri-
teria were pregnancy and presence of other psychiatry or
medical disorders.
In the hyperthyroid group, diagnosis was based on
clinical examinations and thyroid functioning tests. These
evaluations were carried out by an endocrinologist. Thirty-
four patients with overt hyperthyroidism (thyroid stimula-
tion hormone (TSH) < 0.2 and total thyroxine (T4) > 12) and
complaints of anxiety were entered in the study. Exclusion
criteria in this group were positive history of anxiety disor-
ders prior to diagnosis of hyperthyroidism, family history
of anxiety disorders, pregnancy and presence of any other
psychiatry and medical disorder.
The patients, with diagnosis of GAD and hyperthy-
roidism that met the inclusion criteria, were referred for
the evaluation of the clinical characteristics of anxiety.
Hamilton Anxiety rating scale (HAM-A) (11) was instru-
mented to evaluate the overall anxiety severity and anxi-
ety characteristics of the two groups. The test was admin-
istered by a clinical psychologist, who was blind to the di-
agnosis of the patients. She explained each item of the
test in Farsi to the patients and registered their responses.
The HAM-A scale is a comprehensive scale, however, it in-
cludes multiple symptoms under a single item. For ex-
ample the item assessing “respiratory symptoms” includes
both “shortness of breath”, which means that the subject
feels there is not enough air, and “dyspnea” which is some-
what different and means that the subject reports that
he/she feels it is difficult or tiresome to breath. The HAM-A
scale has 14 items, the maximum score is 56 and the score
of each part ranges from 0 to 4.The validity and reliability
of HAM-A has been confirmed by several studies (12, 13).
Independent sample T-Test was used to carry out the
comparison. Statistical assessments were performed by
SPSS for Windows version 12.0.
3. Results
The mean age of the patients was 32.15 years old, and
70.9% were female. Baseline demographic data and thy-
roid functioning levels are depicted in Table 1. The two
groups did not differ significantly regarding gender and
age.
Differences between the two groups on measures of to-
tal anxiety scores and anxiety characteristics are shown in
Table 2. Overall anxiety severity (total score on the HAM-
A) did not differ between the two groups (P = 0.65). The
anxious patients with hyperthyroidism had higher scores
on autonomic symptoms compared to the GAD group (P =
0.003). On the other hand, in the GAD group, scores for fear
and anxious mood were higher (P = 0.001 and P = 0.045,
Table 1. Baseline Demographic Data and Thyroid Function Tests
Hyperthyroidism Generalized Anxiety
Disorder
Gender, Female 24 (70%) 23 (71.87%)
Mean age, y 33.7 30.6
Mean TSH level,mIU/L 12±.02 2.2± 1.5
Mean Total T4 level,
ng/dL
16.4± 2.1 7.5± 1.2
respectively). The other anxiety subscales were not signifi-
cantly different between the two groups.
Table 2. Comparison of Total Anxiety Score and Anxiety Symptoms
Anxiety Symptoms Hyperthyroidism
(Mean)
GAD (Mean) P Value
Anxiousmood 2.00 2.60 0.045
Tension 2.40 1.86 0.093
Fears 0.56 2.13 0.001
Insomnia 2.36 2.16 0.54
Intellectual 2.16 2.20 0.92
Depressedmood 2.36 2.30 0.83
Somatic (muscular) 1.50 1.43 0.86
Somatic (sensory) 1.20 1.00 0.41
Cardiovascular
symptoms
2.50 1.90 0.13
Respiratory
symptoms
1.76 1.66 0.79
Gastrointestinal
symptoms
2.20 1.86 0.33
Genitourinary
symptoms
1.26 1.40 0.68
Autonomic
symptoms
2.40 1.43 0.003
Behavior at
Interview
2.00 2.03 0.90
Total Score 26.46 25.40 0.65
Abbreviation: GAD: generalized anxiety disorder.
4. Discussion
Our study showed that the overall anxiety severity was
the same in GAD patients and patients with anxiety due
to hyperthyroidism. However, patients with GAD demon-
strated more anxious mood (worries, anticipation of worst
and fearful anticipation) and fears (of dark, being alone,
poverty, strangers and other things). On the other hand,
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in the patients with anxiety due to hyperthyroidism, auto-
nomic symptoms (tachycardia, dry mouth, flushing, pallor
and sweating) were more prominent.
Several studies have demonstrated that hyperthy-
roidism is associated with anxiety symptoms (6-9, 12, 13).
Chattopadhyay et al. found that anxiety symptoms were
the most common psychiatry abnormality in grave’s hy-
perthyroidism (9). Some other studies reported that the
psychology symptoms in hyperthyroidism were similar to
anxiety disorders (14, 15). Furthermore, Iocovides et al. in
their study demonstrated that there was no difference in
regards to anxiety severity between patients with anxiety
due to hyperthyroidism and patients with GAD (16). In line
with these studies, our results show that the overall anxiety
severity did not differ between patients of the two groups.
However, there are only a few studies on differentia-
tion of anxiety manifestations of hyperthyroidism from
GAD. In our study, we found that patients with GAD com-
plained about the psychology symptoms of anxiety (anx-
ious mood, worries, anticipation of worst, fearful antici-
pation and fears) more than the anxious hyperthyroid pa-
tients. On the other hand, physical symptoms of anxiety
(tachycardia, dry mouth, flushing, pallor and sweating)
were more observed in patients with anxiety due to hyper-
thyroidism. These differentiating points may be impor-
tant in clinical settings to discriminate GAD from hyper-
thyroidism. Supporting our results, there are studies em-
phasizing that autonomic symptoms like elevated sleep-
ing pulse rate, hot moist palms, sweating and fine tremor
are more commonly present in patients with anxiety due
to hyperthyroidism compared to patients with GAD (17, 18).
On the Other hand, some authors reported that psycholog-
ical profile is not a good differentiating means, and phys-
ical characteristics like preference of cold and avoidance
of heat, excessive eating and weight loss, thyroid bruit, au-
ricular fibrillation, hyperkinetic movements, exophthal-
moses, lid retraction, and lid lag have more powerful dis-
criminating value (19-22).
Neuropsychiatric manifestations triggered by thyroid
dysfunction likely respond well to reestablishment of the
euthyroid state, although some patients have persistent
complaints (7, 23). Therefore, treatment of hyperthy-
roidism and observing psychiatric symptoms that change
following treatment can also help differentiate hyperthy-
roidism from GAD.
This study had a small sample size and our results
need to be considered preliminary, unless larger replica-
tion studies support our findings. Another disadvantage of
our study was that some hyperthyroid patients might have
GAD simultaneously, which was not possible to differenti-
ate in this research.
In conclusion, our research demonstrated that the
overall anxiety severity was the same in GAD and hyperthy-
roidism. However, psychology symptoms of anxiety were
more commonly reported by patients with GAD whereas
the physical symptoms of anxiety were more prominent
in hyperthyroid patients with anxiety. Our findings may
help differentiate these two disorders in the clinic, based
on symptom profile.
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